CD274 and cancer: In fact, antibody-based blockade of the PD-1/PD-L1 interaction leads to durable clinical responses in several types of cancers [225,226,227,228,229] and reviewed elsewhere [230], and has exhibited a therapeutic benefit in chronic HBV and HCV infection [231,232].